-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Therapeutics Q2 FY26 net loss narrows to $5.24 million; R&D expense falls to $1.82 million

PUBT·08/13/2026 20:35:04
Listen to the news
Tempest Therapeutics Q2 FY26 net loss narrows to $5.24 million; R&D expense falls to $1.82 million
  • Tempest Therapeutics posted a GAAP net loss of USD 5.24 million, narrowing from USD 7.87 million a year earlier.
  • Loss per share improved to USD 0.34 from USD 2.07 in the prior-year quarter.
  • R&D expense fell to USD 1.82 million from USD 3.87 million, following reprioritization after the February 2026 asset acquisition.
  • Cash and cash equivalents dropped to USD 779,000 at June 30, 2026 from USD 7.71 million at Dec. 31, 2025.
  • Senlang collaboration set first TPST-4003 patient dosing for Q4 2026, with initial clinical data expected in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131625PRIMZONEFULLFEED9809941) on August 13, 2026, and is solely responsible for the information contained therein.